CAJ | 학술논문

目的：探讨度洛西汀与文拉法辛缓释片治疗躯体形式障碍的临床疗效和安全性。方法：将73例躯体形式障碍患者随机分为两组，研究组患者36例，口服度洛西汀治疗；对照组患者37例，口服文拉法辛缓释片治疗；观察8周。于治疗前及治疗第1、2、4、8周末分别采用汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)及症状自评量表(SCL-90)躯体化因子分评价疗效，用副反应量表(TESS)评定不良反应，将两组患者结果加以分析、比较。结果：治疗后两组患者 HAMD、HAMA、SCL-90躯体化因子评分均较治疗前显著下降(P 均<0.05)。治疗第1、2周末对照组患者 HAMD、HAMA、SCL-90躯体化因子评分较研究组下降更显著(P 均<0.05)。研究组患者治疗的总有效率75%，对照组为78%，两组比较差异无显著性(P>0.05)。研究组患者的 TESS 评分均低于对照组(P 均<0.05)。结论：度洛西汀与文拉法辛缓释片治疗躯体形式障碍疗效显著且相当，依从性好，但度洛西汀不良反应更少。
목적：탐토도락서정여문랍법신완석편치료구체형식장애적림상료효화안전성。방법：장73례구체형식장애환자수궤분위량조，연구조환자36례，구복도락서정치료；대조조환자37례，구복문랍법신완석편치료；관찰8주。우치료전급치료제1、2、4、8주말분별채용한밀이돈억욱량표(HAMD)、한밀이돈초필량표(HAMA)급증상자평량표(SCL-90)구체화인자분평개료효，용부반응량표(TESS)평정불량반응，장량조환자결과가이분석、비교。결과：치료후량조환자 HAMD、HAMA、SCL-90구체화인자평분균교치료전현저하강(P 균<0.05)。치료제1、2주말대조조환자 HAMD、HAMA、SCL-90구체화인자평분교연구조하강경현저(P 균<0.05)。연구조환자치료적총유효솔75%，대조조위78%，량조비교차이무현저성(P>0.05)。연구조환자적 TESS 평분균저우대조조(P 균<0.05)。결론：도락서정여문랍법신완석편치료구체형식장애료효현저차상당，의종성호，단도락서정불량반응경소。
Objective:To explore efficacy and safety of Duloxetine and Venlafaxine sustained-release tablets in treatment of so-matoform disorder. Methods:A total of 73 patients with somatoform disorders were randomly divided into study group (36 cases) and control group (37cases), wherein they were treated with Duloxetine and Venlafaxine sustained-release tablets for 8 weeks, respective-ly. All patients were assessed with Hamilton depression scale (HAMD), Hamilton anxiety scale (HAMA), factor scores of somatiza-tion in symptom checklist-90 (SCL-90) and treatment emergent symptom scale for the efficacy and side effects at the baseline and 1st, 2nd, 4th, 8th weekend of the treatment, and then the results of the two groups were analyzed and compared. Results: The HAMD scores, HAMA scores, and factor scores of somatization in SCL-90 of the two groups decreased significantly after the treatment com-pared with those before the treatment (all P<0. 05). The HAMD scores, HAMA scores, and factor scores of somatization of control group were significantly lower than those of study group at the 1st and 2nd weekends of the treatment (all P<0. 05). The total effective rates of study group and control group were 75% and 78% , respectively; and the difference was not significant (P>0. 05). Conclu-sions: Both Duloxetine and Venlafaxine sustained-release tablets have an evident and equivalent effect, and good compliance in the treatment of somatoform disorder, but the side effects of Duloxetine are fewer.